A 2026 survey of 5,065 U.S
India brings Wegovy into the fatty-liver conversation
Jul 17, 2026
A mouse study explores one way researchers are probing the GLP-1 plateau
A survey shows GLP-1 use moving from a niche treatment into a broader U.S. pattern
Jul 7, 2026
GLP-1 growth is becoming a global access story as well as a U.S. one
Jul 9, 2026
A 2026 national survey found that 11% of adults reported currently using a GLP-1 medicine for weight loss
Employer coverage is still the access question behind obesity medicines
Jul 8, 2026
A federal Medicare bridge program described in 2026 opened a temporary route for eligible beneficiaries to receive
Jul 1, 2026
A review raises a careful question about GLP-1 medicines and binge eating
A review of 25 randomized trials involving 8,069 people found that GLP-1-targeting medicines were associated with fewer binge-eating episodes, less loss-of-control eating, and less emotional eating. The studies covered several medicines and countries, but they did not establish an approved treatment for binge-eating disorder. The signal matters because binge-eating disorder has limited medication options and can be deeply impairing. Most of the trials, however, did not enroll people with a clinical diagnosis of the disorder, so the result cannot predict how a person with that diagnosis will respond.
Research questions about GLP-1 medicines and mental health are still separate questions
A better national mortality picture cannot be assigned to one class of medicines
Jul 4, 2026
A small trial found an aging-biomarker signal, not a way to reverse aging
A designed enzyme shows where protein engineering is heading
Protein design is becoming less like searching for one lucky sequence and more like testing many plausible ones. In this work, researchers used a design model and evolutionary constraints to build variants of a small RNA-guided enzyme. Some variants retained or exceeded the starting enzyme’s activity in laboratory systems, and structural work suggested why. That is a technical advance in making proteins that still function after substantial redesign.
A GLP-1 implant is testing a different delivery idea, not offering a new option yet
Jul 11, 2026
The cancer question around GLP-1 medicines is still early
Jun 19, 2026
Protein design is expanding the research toolkit behind future medicines
Jun 2025
A tool for designing cyclic peptides moves from code to the lab
Oct 2025A 2025 argument about Medicaid coverage put GLP-1 medicines at the center of a state-budget question: whether to ab
A 2025 argument about Medicaid coverage put GLP-1 medicines at the center of a state-budget question: whether to absorb high near-term drug costs in pursuit of possible longer-term health gains. The relevant public action would be made state by state, not by a single national rule. For people enrolled in Medicaid, the consequence is that access can depend on a state benefit design rather than on the existence of a prescription. States face the same basic tension between immediate spending, uncertain savings, and a large potentially eligible population.
The price debate around weight-loss drugs has a policy question behind it
Mar 14, 2025
A West Virginia coverage pilot exposed the cost of stopping a benefit
Dec 2024
A 2024 Medicare decision expanded coverage of certain semaglutide medicines for beneficiaries with qualifying cardi
Apr 3, 2024
Why employer coverage became a fault line for obesity medicines
May 26, 2023